Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Oxycodone prior authorization Medicare?
Oxycodone is a Schedule II controlled substance opioid analgesic. The most commonly prescribed formulation for chronic pain is oxycodone/acetaminophen 5/325mg (generic for Percocet). Extended-release oxycodone (OxyContin) is FDA-approved for around-the-clock management of severe pain in patients who require continuous, long-term opioid treatment and for whom alternative options are inadequate.
Research
Key Stats:
- AMA 2024 Prior Authorization Survey: 93% of physicians report care delays due to PA; practices complete an average of 39 PAs per physician per week, consuming roughly 13 hours of staff time; opioid PAs require 2-3 hours of staff time per request due to additional documentation and compliance requirements
- Opioid PA approval data (PubMed): 89% of oxycodone PAs ultimately approved; 6% denied; 5% canceled before resolution; oxycodone was the most frequently prescribed opioid requiring PA at 31% of all requests
- CMS OIG Medicare Advantage (2024): 3.2 million PA requests denied; 81.7% overturned on appeal; fewer than 11% of beneficiaries actually file appeals
- CMS CY 2026 opioid safety edits: 90 MME/day care coordination edit (mandatory); 7-day acute pain supply limit for opioid-naive patients (mandatory); 200 MME/day hard edit (optional for plans); concurrent opioid-benzodiazepine DUR edit (mandatory)
- CMS-0057-F (effective January 2026): Medicare Advantage plans must respond to PA requests within 72 hours (expedited) or 7 calendar days (standard)
- CMS-0062-P (proposed 2026): would extend ePA requirements to Part D drug coverage with compliance beginning October 2027
- Illinois SB 1828 (2026): one of 8 states prohibiting insurers from requiring PA or step therapy for non-opioid pain medications — makes documenting non-opioid trial history easier for IL providers
- Part D annual out-of-pocket cap: $2,100 in 2026 under the Inflation Reduction Act
State Notes (GA/PA/IL):
- GA: Georgia Medicaid covers oxycodone with PA through MCOs (Amerigroup, CareSource, Peach State); all Schedule II opioids require PA; 7-day initial fill limit for opioid-naive patients (SB 81); PDMP check mandatory before every Schedule II prescription
- PA: Pennsylvania Medicaid covers oxycodone with PA through MCOs (UPMC Health Plan, Highmark Wholecare, Geisinger); PA required for all extended-release/long-acting opioids; step therapy requires failure of at least two non-opioid therapies; 7-day initial fill for acute pain per Act 125 (2016); ABC-MAP PDMP check mandatory; some MCOs require documented urine drug screening
- IL: Illinois Medicaid covers oxycodone with PA through MCOs (Meridian, Molina, CountyCare); SB 1828 (2026) prohibits PA for non-opioid pain alternatives; Illinois PMP check mandatory; cancer pain, palliative care, and sickle cell disease exempt from standard quantity limits
Medicare Part D Opioid Safety Edits That Affect Oxycodone Coverage
90 MME Care Coordination Edit (Mandatory): CMS requires Part D sponsors to implement a care coordination edit when a beneficiary’s cumulative opioid dose reaches 90 morphine milligram equivalents per day. Oxycodone has an MME conversion factor of 1.5x. Oxycodone 10mg x 4 per day = 60 MME/day. At higher doses or with concurrent opioid prescriptions, patients cross the 90 MME threshold quickly. When this edit triggers, the pharmacy claim is rejected at point of sale. The prescriber must provide clinical justification: pain scores, functional assessment, risk stratification (ORT or similar), PDMP report, and urine drug screening.
7-Day Acute Pain Supply Limit (Mandatory): CMS mandates a hard safety edit limiting initial opioid fills for opioid-naive patients to no more than a 7-day supply for acute pain. This does not apply to chronic pain patients with established opioid therapy, but the plan must verify opioid-tolerant status. If the patient’s claims history does not show a prior opioid fill within 60-90 days, the edit may trigger even for chronic pain patients.
200 MME Hard Edit (Optional for Plans): Plans may implement an optional hard edit at 200 MME/day or more. Claims exceeding 200 MME/day are rejected and require prescriber override with extensive clinical documentation. Exemptions: hospice, palliative care, end-of-life care, long-term care residents.
Concurrent Opioid-Benzodiazepine Edit (Mandatory DUR): CMS requires DUR edits flagging concurrent prescriptions of opioids and benzodiazepines. If a patient is on both oxycodone and a benzodiazepine (alprazolam, lorazepam, etc.), the pharmacy claim may reject or generate a soft edit requiring pharmacist-prescriber consultation.
Step-by-Step Process for Submitting an Oxycodone PA Under Medicare
Phase 1: Pre-Submission
Step 1 — Verify formulary status. Check the patient’s specific Part D or MA plan formulary. Confirm which oxycodone formulations are covered, the tier, and all utilization management requirements (PA, step therapy, quantity limits, safety edits). Generic and brand formulations may have different requirements on the same plan.
Step 2 — Check the state PDMP. Log into the state PDMP (Georgia PDMP, Pennsylvania ABC-MAP, or Illinois PMP) and pull the patient’s controlled substance history. Include a screenshot or printout with the PA submission. Most Part D plans require proof of PDMP check within 30 days.
Step 3 — Document non-opioid trial history. Pull the patient’s medication history and document specific dates, doses, duration, and reason for failure for each non-opioid tried. Medicare typically expects documented trials of: acetaminophen, NSAIDs, gabapentin or pregabalin, and sometimes tramadol or duloxetine. Include clinical notes showing why each agent was insufficient.
Step 4 — Gather clinical documentation. Collect: chronic pain diagnosis with specific ICD-10 code, current pain scores, functional assessment, imaging or diagnostic reports supporting the pain diagnosis, current medication list, PDMP report, pain management agreement (if required), and urine drug screening results.
Phase 2: Submission and Follow-Up
Step 5 — Submit the PA request. Use the plan’s preferred method: ePA through the EHR, CoverMyMeds, plan portal, fax, or phone. Include all clinical documentation from Steps 2-4. Incomplete opioid PA submissions are rejected at higher rates — submit everything upfront.
Step 6 — Track the PA timeline. Standard Part D decisions: 72 hours. Expedited (patient health at risk from uncontrolled pain): 24 hours. MA plans under CMS-0057-F: 72 hours expedited, 7 calendar days standard.
Step 7 — Respond to information requests within 24 hours. Common additional requests: updated pain scores, peer-to-peer review scheduling, UDS results, specialist referral documentation. Delays restart the review clock.
Step 8 — Confirm approval details and set renewal tracking. Verify approval duration (typically 6-12 months for opioids), approved quantity per fill, dose restrictions, and renewal date. Set a calendar reminder 30 days before expiration. Opioid PAs expire faster than most other drug PAs.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
ICD-10 Codes and Documentation Requirements for Oxycodone PA
Preferred ICD-10 Codes
Documentation Checklist:
- Chronic pain diagnosis with ICD-10 code tied to diagnostic evidence (imaging, exam findings)
- Non-opioid medication trial history with dates, doses, duration, reason for failure
- Current PDMP report (within 30 days)
- Pain management agreement signed by patient (if required by plan)
- Urine drug screening results (within 90 days for many plans)
- Current pain score (numeric or functional scale)
- Functional assessment showing impact on daily activities
- Prescriber letter of medical necessity (for denials/appeals)
Using generic code G89.4 alone without supporting specific diagnosis codes reduces approval rates. Pair it with the specific anatomical/condition code whenever possible.
Common Oxycodone PA Denial Reasons and How to Prevent Them
Denial 1: Incomplete non-opioid trial documentation. The PA states “failed conservative therapy” without specific dates, doses, and duration for each agent tried. Fix: document each trial individually with start date, end date, maximum dose, and specific reason for discontinuation.
Denial 2: Missing or expired PDMP report. Fix: pull a fresh PDMP report (within 30 days) and attach it to every opioid PA submission.
Denial 3: 90 MME safety edit rejection. Fix: calculate total daily MME before submitting. If it exceeds 90, include clinical justification for the dose, ORT score, and prescriber attestation with the PA.
Denial 4: Step therapy not completed. Fix: check the plan’s specific step therapy ladder before submitting. Each plan defines its own required agents.
Denial 5: Quantity limit exceeded without exception request. Commonly 120-180 tablets per 30 days for immediate-release. Fix: submit a separate quantity exception request with clinical justification if prescribed quantity exceeds plan limits.
Denial 6: Plan change without PA transfer. Fix: identify plan changes during annual enrollment and submit new PAs to the incoming plan before the effective date.
How to Appeal an Oxycodone PA Denial Under Medicare
Level 1: Redetermination (by the Part D plan)
- File within 60 days of the denial notice
- Plan must respond within 7 calendar days (72 hours if expedited)
- Include a letter of medical necessity addressing why oxycodone is required over formulary alternatives
- Request a peer-to-peer review — for opioid PAs, peer-to-peer reviews are more commonly granted and can be decisive
Level 2: Independent Review Entity (IRE)
- If the plan upholds denial, escalate to the IRE within 60 days
- The IRE is independent of the Part D plan
- Decision within 7 calendar days (72 hours expedited)
- Include any new clinical evidence: specialist consultation, updated imaging, pain management referral
Level 3: Administrative Law Judge (ALJ)
- Available if amount in controversy meets the threshold ($195 in 2026)
- For ongoing oxycodone prescriptions, annual cost easily meets this threshold
- File within 60 days of the IRE decision
CMS OIG found 81.7% of Medicare Advantage PA denials were overturned on appeal. Fewer than 11% of beneficiaries actually file. For controlled substance PAs, filing with complete documentation yields significantly better outcomes than abandoning the request.
What most PA guides do not admit: A high appeal overturn rate is not a win. It means the plan is denying things it should have approved on first pass, and the cost of that backlog sits on your clinic, not the insurer. If you are getting more than 15% of your opioid PAs denied, the real fix is not better appeals. It is a submission-side audit of which plan-specific fields, trial sequences, and PDMP attachments are missing from your template. Fix that and denials drop before they ever hit appeal.
State Medicaid Opioid PA Rules: Georgia, Pennsylvania, Illinois
Georgia: Georgia Medicaid covers oxycodone for chronic pain with PA through MCOs (Amerigroup, CareSource, Peach State). PA required for all Schedule II opioids. Step therapy: documented non-opioid trial required (acetaminophen, NSAIDs, gabapentin). Quantity limits: 7-day initial fill for opioid-naive patients per Georgia SB 81. Georgia PDMP check mandatory before every Schedule II prescription.
Pennsylvania: Pennsylvania Medicaid covers oxycodone with PA through MCOs (UPMC Health Plan, Highmark Wholecare, Geisinger). PA required for all extended-release/long-acting opioids. Step therapy: failure of at least two non-opioid therapies required. Quantity limits: 7-day initial fill for acute pain per Act 125 (2016); chronic pain requires a signed pain management agreement. Pennsylvania ABC-MAP PDMP check mandatory; some MCOs also require documented urine drug screening.
Illinois: Illinois Medicaid covers oxycodone with PA through MCOs (Meridian, Molina, CountyCare). PA required for extended-release opioids. Illinois SB 1828 (2026) prohibits insurers from requiring PA or step therapy for non-opioid pain treatments, making non-opioid trial documentation easier to compile. Illinois PMP check mandatory. Cancer pain, palliative care, and sickle cell disease are exempt from standard opioid quantity limits.
Why Practices Outsource Controlled Substance Prior Authorization
Opioid PAs are the most documentation-intensive PA category. They require PDMP checks, non-opioid trial records, pain management agreements, UDS results, safety edit overrides, and often peer-to-peer reviews. A single oxycodone PA can consume 2-3 hours of staff time.
At $25-$35/hour for in-house staff, each opioid PA costs $50-$105 in direct labor. For a pain management practice processing 20+ opioid PAs per week, that is $52,000-$109,200 per year in PA labor alone.
Staffingly’s PA specialists handle the full opioid PA lifecycle: formulary verification, PDMP documentation, non-opioid trial compilation, safety edit override preparation, PA submission, denial management, appeals, and renewal tracking.
- 800+ providers served
- 99.2% clean claim rate
- $399/week (volume discounts to $299/week) — 70% savings vs. in-house billing staff
- SOC 2 Type II, HITRUST, ISO 27001, HIPAA compliant
- Go-live in 48-72 hours
- 50+ EHR platforms supported for ePA submission
- 15-Day Risk-Free Pilot
FAQ Section
Q: Does Medicare Part D cover oxycodone for chronic pain? A: Most Medicare Part D plans cover generic oxycodone/acetaminophen on Tier 1-2 and some cover extended-release oxycodone (Tier 3-4) with prior authorization. Coverage requires a chronic pain diagnosis, documented non-opioid trial history, and compliance with CMS opioid safety edits. Brand OxyContin is excluded from many Part D formularies.
Q: What documentation does Medicare require for an oxycodone PA? A: Chronic pain diagnosis with specific ICD-10 code, documented non-opioid medication trials (dates, doses, duration, failure reason), current PDMP report (within 30 days), pain management agreement (if plan requires it), urine drug screening results, current pain scores, and a letter of medical necessity explaining why oxycodone is needed over alternatives.
Q: What is the 90 MME safety edit and how does it affect oxycodone? A: CMS requires Part D plans to implement a care coordination edit when a patient’s cumulative daily opioid dose reaches 90 morphine milligram equivalents. Oxycodone has an MME conversion factor of 1.5x. If this edit triggers at the pharmacy, the claim is rejected until the prescriber provides clinical justification including pain scores, risk stratification, and PDMP documentation.
Q: How long does oxycodone prior authorization take under Medicare? A: Standard Part D decisions take up to 72 hours. Expedited requests (uncontrolled pain threatening patient health) must be decided within 24 hours. Medicare Advantage plans must respond within 72 hours (expedited) or 7 calendar days (standard) under CMS-0057-F. Opioid PAs may take longer due to additional documentation review and peer-to-peer requests.
Q: What ICD-10 codes should I use for oxycodone prior authorization? A: Use specific codes: M54.5 (low back pain), M54.2 (cervicalgia), G89.29 (other chronic pain), or the relevant cancer pain code (C00-D49 range). Avoid using only G89.4 (chronic pain syndrome) without a supporting specific diagnosis code — it increases denial rates.
Q: What do I do if oxycodone PA is denied by Medicare? A: Request a redetermination from the Part D plan within 60 days. Include a letter of medical necessity, all clinical documentation, and request a peer-to-peer review. If denied again, escalate to the Independent Review Entity. CMS OIG data shows 81.7% of Medicare PA denials are overturned on appeal.
Q: Is oxycodone step therapy required under Medicare Part D? A: Most Part D plans require documented trials of non-opioid alternatives before approving oxycodone. Commonly required agents include acetaminophen, NSAIDs, gabapentin or pregabalin, and sometimes tramadol or duloxetine. Each trial must be documented with specific dates, doses, duration, and the reason it was insufficient.
Frequently Asked Questions
For controlled-substance and Medicare PA support, these dedicated service teams handle the documentation-heavy parts of an oxycodone request:
- Medicare Prior Authorization Services for Part D formulary, safety-edit, and CMS-0057-F timeline work.
- Step Therapy Override Services to compile non-opioid trial history and override requests.
- Peer-to-Peer Review Services to schedule and prepare prescriber-to-reviewer calls on denials.
